Vermillion, Inc. (NASDAQ:VRML) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

Vermillion, Inc. (NASDAQ:VRML) Files An 8-K Regulation FD Disclosure
Item 7.01.  Regulation FD Disclosure.

A copy of the investor presentation that Vermillion, Inc. plans to use in conjunction with meetings, beginning on January 9,  2017, during the J.P. Morgan Healthcare Conference is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. 







Item 9.01Financial Statements and Exhibits.



(d)         Exhibit No.Description.

99.1Vermillion, Inc. investor presentation dated January 9, 2017


About Vermillion, Inc. (NASDAQ:VRML)

Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.

Vermillion, Inc. (NASDAQ:VRML) Recent Trading Information

Vermillion, Inc. (NASDAQ:VRML) closed its last trading session up +0.14 at 1.28 with 157,336 shares trading hands.